Paper559669
Metronidazole: review of uses and toxicity.
Roe FJ. J Antimicrob Chemother, 1977. Cited by 111 papers, by iCite.
Cite this record
ConductScience Library. Metronidazole: review of uses and toxicity. Papers, record 559669. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/559669
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Metronidazole | Major topic |
| Amebiasis | |
| Anaerobiosis | |
| Animals | |
| Bacterial Infections | |
| Female | |
| Giardiasis | |
| Humans | |
| Radiation-Sensitizing Agents | |
| Trichomonas Vaginitis |
Source PubMed
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 111 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39179514 | Novel Prodrug Strategies for the Treatment of Tuberculosis. | Chem Asian J | 2024 | https://conductscience.org/library/papers/39179514 | PubMed |
| 35782149 | An Unusual U2AF2 Inhibits Splicing and Attenuates the Virulence of the Human Protozoan Parasite Entamoeba histolytica. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/35782149 | PubMed |
| 35624678 | Insights into the Mechanisms of Lactobacillus acidophilus Activity against Entamoeba histolytica by Using Thiol Redox Proteomics. | Antioxidants (Basel) | 2022 | https://conductscience.org/library/papers/35624678 | PubMed |
| 35548465 | An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/35548465 | PubMed |
| 34439488 | Entamoeba histolytica Adaption to Auranofin: A Phenotypic and Multi-Omics Characterization. | Antioxidants (Basel) | 2021 | https://conductscience.org/library/papers/34439488 | PubMed |
| 33302377 | Lactoferrin and Its Derived Peptides: An Alternative for Combating Virulence Mechanisms Developed by Pathogens. | Molecules | 2020 | https://conductscience.org/library/papers/33302377 | PubMed |
| 32023994 | Microbiological Air Quality and Drug Resistance in Airborne Bacteria Isolated from a Waste Sorting Plant Located in Poland-A Case Study. | Microorganisms | 2020 | https://conductscience.org/library/papers/32023994 | PubMed |
| 30175074 | High-Throughput Screening of Entamoeba Identifies Compounds Which Target Both Life Cycle Stages and Which Are Effective Against Metronidazole Resistant Parasites. | Front Cell Infect Microbiol | 2018 | https://conductscience.org/library/papers/30175074 | PubMed |
| 29089593 | New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development. | J Antibiot (Tokyo) | 2017 | https://conductscience.org/library/papers/29089593 | PubMed |
| 28410582 | Metronidazole for the treatment of Tritrichomonas foetus in bulls. | BMC Vet Res | 2017 | https://conductscience.org/library/papers/28410582 | PubMed |
| 25229475 | Effect of oral administration of metronidazole or prednisolone on fecal microbiota in dogs. | PLoS One | 2014 | https://conductscience.org/library/papers/25229475 | PubMed |
| 21984744 | Comment on: Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. | J Antimicrob Chemother | 2012 | https://conductscience.org/library/papers/21984744 | PubMed |
| 21879846 | Nitroimidazoles for the treatment of TB: past, present and future. | Future Med Chem | 2011 | https://conductscience.org/library/papers/21879846 | PubMed |
| 19149517 | Vaccines and photodynamic therapies for oral microbial-related diseases. | Curr Drug Metab | 2009 | https://conductscience.org/library/papers/19149517 | PubMed |
| 8698362 | An in vitro metronidazole susceptibility test for trichomoniasis using the InPouch TV test. | Genitourin Med | 1996 | https://conductscience.org/library/papers/8698362 | PubMed |
| 7039761 | Metronidazole in a single dose for the treatment of trichomoniasis. Failure of a 1-g single dose. | Br J Vener Dis | 1982 | https://conductscience.org/library/papers/7039761 | PubMed |
| 6983379 | Metronidazole resistance of Trichomonas vaginalis as a cause of treatment failure in trichomoniasis--A case report. | Br J Vener Dis | 1982 | https://conductscience.org/library/papers/6983379 | PubMed |
| 6783642 | Metronidazole and the isolation of temperature-sensitive photosynthetic mutants in cyanobacteria. | J Bioenerg Biomembr | 1980 | https://conductscience.org/library/papers/6783642 | PubMed |
| 6340904 | Clinical pharmacokinetics of metronidazole. | Clin Pharmacokinet | 1983 | https://conductscience.org/library/papers/6340904 | PubMed |
| 3830698 | Mechanism of toxicity of nitro compounds used in the chemotherapy of trichomoniasis. | Environ Health Perspect | 1985 | https://conductscience.org/library/papers/3830698 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/559669
GET https://conductscience.org/api/papers/v1/559669/cited_by?page=2